The analysis of the patient workup for the diagnosis of CHD demonstrated that the improved clinical accuracy of the HyperQ compared to standard stress testing can potentially lead to a reduction of 13% in unnecessary cardiac imaging tests and a reduction in unwarranted angiographies with healthcare savings exceeding $1bn annually.

In addition, analysis of CHD patient care costs demonstrated that the use of HyperQ stress test reduces the number of undiagnosed patients and thus leads to an improvement in cardiac care and the accuracy of diagnosing CHD patients. Based on published data, routine use of the HyperQ will reduce the number of acute cardiac events (including heart attacks), and lower mortality resulting from CHD while reducing the overall costs to the health care system.

BSP intends to use the analysis’ results in discussions with US insurers, aimed at allocating an elevated coverage code for the HyperQ procedure. HyperQ technology and the great economic benefit it offers correlate perfectly with the current administration’s healthcare reform, supporting more cost-effective care and reducing unwarranted expensive and radioactive procedures.

BSP is a developer and marketer of systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease (IHD) based on its proprietary HyperQ technology.